CardiAQ Valve Technologies (CVT) is developing the world’s first self-conforming and self-anchoring technology for transcatheter mitral valve implantation. The initial indication for this percutaneous valve will be treating functional mitral regurgitation to prevent heart failure. CVT is located in Irvine, California and is led by CEO Brent Ratz with significant direction from Board of Director member (and former CoreValve investor) Rob Michiels. Nine months after our initial investment CVT attracted follow-on funding from an angel group with significant experience in heart valves.  http://www.cardiaq.com/

< Back to Portfolio